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Abstract
Background: Recent reports have shown that vitamin D status was inversely associated with the risk of various cancers.
However, few studies examined the association between vitamin D levels and risk of skin cancer.
Methods: We prospectively evaluated the association between baseline plasma 25(OH)D levels and the risk of incident
squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) among 4,641 women from the Nurses’ Health Study (NHS)
and the NHS II with 510 incident BCC cases and 75 incident SCC cases. We used multivariate logistic regression models to
calculate odds ratios (ORs) and 95% confidence intervals (CIs).
Results: Plasma 25(OH)D levels were positively associated with risk of BCC after adjusting for age at blood draw, season of
blood draw, lab batch, hair color, burning tendency, the number of sunburns, and ultra-violet B flux of residence at blood
collection. Women in the highest quartile of 25(OH)D had more than 2-fold increased risk of BCC compared with women in
the lowest quartile (OR=2.07, 95% CI=1.52–2.80, P for trend ,0.0001). We also found a significantly positive association
between plasma 25(OH)D levels and SCC risk after adjusting for the same covariates (OR, highest vs. lowest quartile =3.77,
95% CI=1.70–8.36, P for trend =0.0002).
Conclusion: In this prospective study of women, plasma vitamin D levels were positively associated with non-melanoma
skin cancer risk. Considering that most circulating vitamin D is due to sun exposure, the positive association between
plasma vitamin D and non-melanoma skin cancer is confounded by sun exposure. Our data suggest that one-time
measurement of plasma vitamin D levels may reasonably reflect long-term sun exposure and predict the risk of non-
melanoma skin cancer.
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Introduction
Skin cancer, the most common malignancy, has been increasing
rapidly over the past decades in the United States, especially in
women [1–3]. Mounting epidemiologic evidence has suggested
that vitamin D may be associated with reduced risk of various
types of cancers, including colorectal [4], prostate [5], breast [6],
pancreatic [7], and lung cancers [8]. However, few studies have
examined the association between vitamin D levels and risk of skin
cancer, and the data are inconsistent [9–11].
It is more difficult to study the relationship between vitamin D
and skin cancer than other internal cancers because vitamin D is
predominantly produced in the skin by ultraviolet B (UVB)
exposure, which is the well-established risk factor for skin cancer.
UVB exposure-synthesized vitamin D in the skin usually
contributes 80–90% to total vitamin D in the human body [12].
Only small amount of vitamin D is derived from other sources
including dietary intake. 25-hydroxyvitamin D [25(OH)D] is
produced in the liver by a hydroxylation reaction [13]. Circulating
plasma 25(OH)D is considered to be the best biomarker of vitamin
D status because it reflects the total vitamin D levels [14]. Three
epidemiologic investigations have suggested conflicting associa-
tions of skin cancer with vitamin D levels [9–11]. In an analysis of
the Osteoporotic Fractures in Men Study, inverse association
between plasma vitamin D levels and risk of non-melanoma skin
cancer in elderly men was found [9]. However, in two other recent
analyses of health maintenance organization populations, higher
plasma vitamin D levels were significantly associated with
increased risk of non-melanoma skin cancer [10,11]. Although
experimental studies have shown that vitamin D treatment can
inhibit proliferation of melanoma and basal cell carcinomas in vitro
[15,16], recent evidence in a large cohort of postmenopausal
women suggests that daily supplementation of vitamin D did not
reduce incidence of skin cancer [17]. However, this study using
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35211low dose vitamin D supplementation (400 IU/day) may not offer
informative evidence regarding the potential influence of vitamin
D status on skin cancer development [17].
Here we prospectively assess the association between plasma
25(OH)D levels and the risk of non-melanoma skin cancer in
a nested case-control study among women from two large ongoing
cohort studies: the Nurses’ Health Study (NHS) and NHS II.
Methods
Ethics Statement
The institutional review board of Brigham and Women’s
Hospital approved this study. Participants’ completion and return
of the self-administered questionnaire was considered to imply
informed consent.
NHS Nested Case-control Study
In 1976, 121,700 female registered nurses between 30 and
55 years old were enrolled in the NHS. Women completed an
initial questionnaire and have been followed biennially by
questionnaire to update information on exposure status and to
identify newly diagnosed case subjects of cancer and other medical
conditions. Between 1989 and 1990, blood samples were collected
from 32,826 participants for analysis. Measurements of plasma
25(OH)D levels were available from a subset of the women who
served as controls in several nested case-control studies of chronic
diseases conducted previously, including breast cancer, colon
polyps, colon cancer and ovarian cancer [18–21]. Eligible cases in
this study were Caucasian women with incident skin squamous cell
carcinoma (SCC) or basal cell carcinoma (BCC) occurring after
blood collection but before 2008. The rest of the subjects were
controls. Participants who had previously diagnosed skin cancer
before blood collection were excluded from the analysis. The
nested case-control study consisted of 387 BCC cases, 67 SCC
cases, and 1,641 controls.
NHS II Nested Case-control Study
The NHS II was established in 1989 among 116,609 female
registered nurses between the ages of 25 and 42. Participants
completed biennial mailed questionnaires to update exposure
status and disease diagnoses. Between 1996 and 1999, 29,611
participants provided blood samples. We used all the controls from
previous nested case-control studies of chronic disease within the
NHS II blood cohort that had been analyzed for vitamin D,
including hypertension, breast cancer and ovarian cancer
[19,22,23]. The inclusive and exclusive conditions of cases and
controls were the same as for the NHS. Eligible cases were
Caucasian women with incident skin SCC or BCC occurring after
blood collection and the rest of the subjects were controls. The
follow-up ended in 2007. Participants who had previously
diagnosed skin cancer before blood collection were excluded.
The nested case-control study consisted of 123 BCC cases, 8 SCC
cases, and 2,415 controls.
Identification of BCC and SCC
We have routinely identified cases of BCC and SCC in both
cohorts. Participants reported new diagnoses biennially. With their
permission, participants’ medical records were obtained and
reviewed by physicians to confirm their self-reported diagnosis.
Only pathologically confirmed invasive SCC cases were included
in this study. Medical records were not obtained for self-reported
cases of BCC, but the validity of BCC self-reports was more than
90% in validation studies in our cohorts in early years [24,25]. In
this analysis, cases were diagnosed after blood collection and up to
2008 (NHS) and 2007 (NHS II).
Measurement of Plasma 25(OH)D
Plasma 25(OH)D concentrations were measured using radio-
immunoassay or chemiluminescence immunoassay, which have
been described in detail previously [26,27]. In the NHS,
laboratory assays were completed in 14 batches of 4 studies from
1996 to 2004 (3 batches in 1996, 4 batches in 2000, and 7 batches
in 2004). In the NHS II, blood samples were assayed in 3 batches
of 3 studies (1 batch in 2003 and 2 batches in 2005). Blinded
replicate quality-control samples were interspersed throughout the
sets for assessing variability. The intra-assay coefficients of
variation (CV) were ,17.6%.
Statistical Analysis
In the nested case-control study of SCC or BCC, 25(OH)D
measurements (continuous in ng/mL) were categorized into
quartiles according to the distribution in control population of
Table 1. Characteristics by quartile of plasma vitamin D concentrations in NHS and NHS II.
25-Hydroxyvitamin D concentrations, ng/mL
NHS NHS II
1st quartile 2nd quartile 3rd quartile 4th quartile 1st quartile 2nd quartile 3rd quartile 4th quartile
n 484 518 535 558 629 629 639 649
Age at blood draw (y) 57.5(7.1) 57.6(6.7) 57.9(6.9) 58.0(6.8) 44.6(4.2) 44.0(4.2) 43.6(4.4) 43.4(4.4)
Red or blonde hair color (%) 16.7 16.1 15.9 18.7 19.3 20.1 23.6 20.3
Burning tendency (%) 35.6 38.9 38.4 32.2 33.0 25.7 24.1 24.1
Numbers of sunburns ($5, %) 5.7 6.3 8.8 6.3 8.8 8.8 10.2 10.1
Season of blood draw
Summer (%) 20.7 30.9 30.1 36.6 10.1 15.5 22.3 28.8
Spring and Fall (%) 45.3 48.3 43.9 44.4 57.4 57.9 57.6 56.5
Winter (%) 34.1 20.9 26.0 19.0 32.5 26.6 20.1 14.8
UVB flux (.113, %) 26.1 28.6 38.4 37.4 41.3 41.8 48.5 50.5
Values are presented as means (Standard deviation) or percentages.
doi:10.1371/journal.pone.0035211.t001
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confidence intervals (95% CIs) were calculated to examine the
relationship between plasma 25(OH)D levels and SCC or BCC by
multivariate logistic regression models. Age at blood draw (in
years), season of blood draw [summer (June-August), fall
(September-November), winter (December-February), and spring
(March-May)], and laboratory batch were included as indepen-
dent variables in all models. Hair color (1=red, 2=blonde,
3=light brown, 4=dark brown, 5=black), burning tendency
(1=practically none, 2=some redness only, 3=burn, 4=painful
burn, 5=painful burn with blisters), the number of sunburns
(1=never, 2=1–2, 3=3–5, 4=$6), and average annual UV-B
flux at residence (#113 and .113) were also adjusted for in the
multivariate models. Pooled analyses of two cohort studies were
conducted by merging data sets.
A previous study indicated that seasonal variation may
introduce biased results of 25(OH)D levels [28]. Therefore, we
conducted stratified analysis to test the interaction of vitamin D
and season of blood draw. We modeled season of blood draw as
a three-category variable (summer, spring and fall, winter). We
tested two multiplicative interaction terms by the likelihood ratio
test, comparing the model with the interaction terms with the
model containing just the main effects of vitamin D and season of
blood draw variables, along with the same covariates. To test
interaction of vitamin D and UVB flux, we modeled UVB flux as
a dichotomous variable (113 as a cutoff point). We tested one
multiplicative interaction term by the likelihood ratio test. Finally,
to summarize multiple variables, we constructed a multivariate
confounder score [29] to create a pigmentation score for BCC.
Briefly, we applied the logistic regression coefficients from
a multivariate model including age, hair color, burning tendency,
and the number of sunburns of BCC to each individual’s values for
the latter three of these variables and summed the values to
compute a pigmentation score. We used this score to identify
participants with light and dark pigmentation phenotypes based on
the median score.
We tested one multiplicative interaction term between vitamin
D and pigmentation by the likelihood ratio test. Statistical analyses
were conducted using SAS software (version 9, SAS Institute,
Cary, NC). All statistical tests were two-sided.
Results
The characteristics of women by quartiles of plasma 25(OH)D
concentration in two cohorts are presented in Table 1. Women
who provided blood samples in summer tended to have higher
25(OH)D levels than those whose blood was drawn in winter,
which is consistent with previously published data [30]. In
addition, women with higher 25(OH)D levels were more likely
to reside in areas of higher UVB flux.
The associations between plasma vitamin D levels and BCC
and SCC were examined separately (Tables 2 and 3). Similar
significantly positive findings were obtained between plasma
25(OH)D and risk of BCC in both cohorts in multivariate models
(P for trend ,0.0001 and =0.01). Women in the highest quartile
of 25(OH)D had about 2-fold increased risk of BCC compared
with women in the lowest quartile, both in NHS (OR=2.28, 95%
CI=1.58–3.29) and in NHS II (OR=1.93, 95% CI=1.10–3.37).
Results were similar when combining the data of NHS and NHS
Table 2. Odds ratios of BCC by quartile of plasma vitamin D concentrations in NHS and NHS II.
25-Hydroxyvitamin D concentrations, ng/mL P for trend
1st quartile 2nd quartile 3rd quartile 4th quartile
NHS
Quartile values #20.4 20.4–27.0 27.0–34.2 .34.2
n, case/control 69/406 86/420 108/405 124/410
OR
a 1.00(reference) 1.21(0.85–1.72) 1.63(1.16–2.30) 2.25(1.58–3.23) ,.0001
OR
b 1.00(reference) 1.19(0.83–1.69) 1.59(1.12–2.25) 2.28(1.59–3.29) ,.0001
OR
c 1.00(reference) 1.18(0.83–1.68) 1.57(1.11–2.23) 2.28(1.58–3.29) ,.0001
NHS II
Quartile values #19.6 19.6–25.5 25.5–31.4 .31.4
n, case/control 24/604 26/602 34/603 39/606
OR
a 1.00(reference) 1.19(0.67–2.10) 1.62(0.93–2.81) 1.93(1.12–3.35) 0.01
OR
b 1.00(reference) 1.20(0.68–2.13) 1.64(0.94–2.86) 1.94(1.11–3.38) 0.01
OR
c 1.00(reference) 1.20(0.67–2.13) 1.63(0.93–2.85) 1.93(1.10–3.37) 0.01
Total
n, case/control 93/1010 112/1022 142/1008 163/1016
OR
d 1.00(reference) 1.19(0.88–1.61) 1.59(1.19–2.13) 2.07(1.54–2.79) ,.0001
OR
e 1.00(reference) 1.17(0.87–1.59) 1.55(1.16–2.08) 2.07(1.53–2.80) ,.0001
OR
f 1.00(reference) 1.17(0.86–1.58) 1.54(1.15–2.07) 2.07(1.52–2.80) ,.0001
Abbreviation: OR, odds ratio.
aAdjusted for age at blood draw, season of blood draw, lab batch.
bAdjusted for age at blood draw, season of blood draw, lab batch, hair color, burning tendency, numbers of sunburns.
cAdjusted for age at blood draw, season of blood draw, lab batch, hair color, burning tendency, numbers of sunburns, UVB flux.
dAdjusted for age at blood draw, season of blood draw, lab batch, cohort.
eAdjusted for age at blood draw, season of blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns.
fAdjusted for age at blood draw, season of blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns, UVB flux.
doi:10.1371/journal.pone.0035211.t002
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25-Hydroxyvitamin D concentrations, ng/mL P for trend
1st quartile 2nd quartile 3rd quartile 4th quartile
NHS
Quartile values #20.4 20.4–27.0 27.0–34.2 .34.2
n, case/control 9/406 12/420 22/405 24/410
OR
a 1.00(reference) 1.43(0.59–3.47) 2.84(1.27–6.37) 3.56(1.56–8.13) 0.0006
OR
b 1.00(reference) 1.48(0.60–3.60) 2.95(1.30–6.70) 3.79(1.63–8.80) 0.0004
OR
c 1.00(reference) 1.49(0.61–3.66) 3.04(1.33–6.95) 3.96(1.68–9.34) 0.0004
NHS II
Quartile values #19.6 19.6–25.5 25.5–31.4 .31.4
n, case/control 1/604 1/602 2/603 4/606
OR
a 1.00(reference) 1.03(0.06–16.79) 1.94(0.16–22.76) 3.43(0.34–34.42) 0.20
OR
b 1.00(reference) 1.33(0.08–22.46) 2.54(0.20–32.28) 4.22(0.39–45.28) 0.17
OR
c 1.00(reference) 1.48(0.08–27.86) 2.62(0.19–36.30) 4.95(0.41–59.28) 0.15
Total
n, case/control 10/1010 13/1022 24/1008 28/1016
OR
d 1.00(reference) 1.37(0.59–3.18) 2.73(1.27–5.87) 3.62(1.67–7.84) 0.0002
OR
e 1.00(reference) 1.43(0.61–3.33) 2.87(1.32–6.22) 3.87(1.76–8.49) 0.0001
OR
f 1.00(reference) 1.40(0.60–3.28) 2.81(1.29–6.12) 3.77(1.70–8.36) 0.0002
aAdjusted for age at blood draw, season of blood draw, lab batch.
bAdjusted for age at blood draw, season of blood draw, lab batch, hair color, burning tendency, numbers of sunburns.
cAdjusted for age at blood draw, season of blood draw, lab batch, hair color, burning tendency, numbers of sunburns, UVB flux.
dAdjusted for age at blood draw, season of blood draw, lab batch, cohort.
eAdjusted for age at blood draw, season of blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns.
fAdjusted for age at blood draw, season of blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns, UVB flux.
doi:10.1371/journal.pone.0035211.t003
Table 4. Odds ratios of BCC by quartile of plasma vitamin D concentrations in NHS and NHS II (stratified by season of blood draw).
season of blood draw 25-Hydroxyvitamin D concentrations, ng/mL
d
P for trend
1st quartile 2nd quartile 3rd quartile 4th quartile
Summer
n, case/control 25/138 33/224 44/259 56/333
OR
a 1.00(reference) 0.73(0.40–1.34) 0.90(0.50–1.64) 0.95(0.53–1.72) 0.81
OR
b 1.00(reference) 0.68(0.37–1.27) 0.88(0.48–1.62) 0.93(0.50–1.70) 0.82
OR
c 1.00(reference) 0.68(0.37–1.27) 0.88(0.48–1.62) 0.93(0.51–1.71) 0.81
Spring and fall
n, case/control 41/536 61/550 84/517 95/516
OR
a 1.00(reference) 1.46(0.93–2.29) 2.26(1.46–3.49) 3.08(1.99–4.78) ,.0001
OR
b 1.00(reference) 1.45(0.92–2.29) 2.11(1.36–3.29) 2.97(1.90–4.63) ,.0001
OR
c 1.00(reference) 1.45(0.92–2.29) 2.10(1.35–3.28) 2.97(1.90–4.63) ,.0001
Winter
n, case/control 37/331 31/243 38/229 39/162
OR
a 1.00(reference) 1.38(0.79–2.40) 1.41(0.81–2.45) 2.29(1.27–4.13) 0.01
OR
b 1.00(reference) 1.35(0.76–2.40) 1.47(0.83–2.60) 2.58(1.39–4.77) 0.005
OR
c 1.00(reference) 1.33(0.75–2.37) 1.44(0.81–2.57) 2.53(1.36–4.72) 0.006
aAdjusted for age at blood draw, lab batch, cohort.
bAdjusted for age at blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns.
cAdjusted for age at blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns, UVB flux.
dP for interaction between season of blood draw and 25-hydroxyvitamin D is 0.09 after adjusted for age at blood draw, lab batch, cohort.
doi:10.1371/journal.pone.0035211.t004
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(Table 2).
We noted significantly positive associations between quartiles of
25(OH)D levels and SCC in NHS (OR=3.96, 95% CI=1.68–
9.34, P for trend =0.0004). In NHS II, although a similar trend
was observed, the result was not statistically significant because
only eight cases were identified. Overall, the positive association
between 25(OH)D levels and SCC was significant after combining
the two cohorts (P for trend =0.0002). Women in the highest
quartile of 25(OH)D had more than a 3-fold increased risk for
SCC compared with women in the lowest quartile (OR=3.77,
95% CI=1.70–8.36) (Table 3).
We further examined the association between plasma 25(OH)D
levelsandBCCriskstratifiedbyseasonofblooddraw,UVBflux,and
pigmentation (Tables 4, 5, 6). There was a significant positive
association between 25(OH)D and risk of BCC among women with
bloodcollectioninspring/fall(OR=2.97,95%CI=1.90–4.63)orin
winter (OR=2.53, 95% CI=1.36–4.72), whereas no association
was observed among women with blood collection in summer
(OR=0.93, 95% CI=0.51–1.71) (P for interaction = 0.09)
(Table 4). In the stratified analysis by UVB flux, women who
lived in lower UVB flux (#113) areas tended to have higher
OR (2.66, 95% CI= 1.78–3.97) when comparing the top to
bottom quartile of 25(OH)D levels (P for interaction=0.07)
(Table 5). The positive association between 25(OH)D and risk of
BCC appeared to be stronger among women with light
pigmentation (P for interaction=0.15) (Table 6).
Discussion
In this study, higher plasma 25(OH)D levels were associated
with greater non-melanoma skin cancer risk among women
from two large cohorts. In subgroup analysis, higher plasma
25(OH)D tended to increase risk of BCC in women whose
blood was collected outside the summer season, who were from
areas with less UVB flux (#113), and among those with light
pigmentation. To our knowledge, the current study is one of the
largest to provide important evidence on the association of pre-
diagnostic plasma 25(OH)D levels with non-melanoma skin
cancer.
Vitamin D is predominantly produced in the skin by UVB
exposure, which usually contributes 80–90% to total vitamin D in
the human body [12]. Our data suggest that one-time measure-
ment of plasma vitamin D levels may reasonably reflect long-term
sun exposure. The validity of single 25(OH)D measures was also
Table 5. Odds ratios of BCC by quartile of plasma vitamin D concentrations in NHS and NHS II (stratified by UVB flux).
UVB flux 25-Hydroxyvitamin D concentrations, ng/mL
c
P for trend
1st quartile 2nd quartile 3rd quartile 4th quartile
#113
n, case/control 60/666 88/648 94/564 113/556
OR
a 1.00(reference) 1.49(1.02–2.17) 1.82(1.24–2.67) 2.62(1.77–3.89) ,.0001
OR
b 1.00(reference) 1.49(1.02–2.18) 1.81(1.23–2.67) 2.66(1.78–3.97) ,.0001
.113
n, case/control 43/343 37/374 72/443 78/458
OR
a 1.00(reference) 0.79(0.47–1.31) 1.24(0.79–1.95) 1.45(0.90–2.33) 0.04
OR
b 1.00(reference) 0.80(0.47–1.34) 1.25(0.78–1.98) 1.52(0.94–2.46) 0.03
aAdjusted for age at blood draw, season of blood draw, lab batch, cohort.
bAdjusted for age at blood draw, season of blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns.
cP for interaction between UVB flux and 25-hydroxyvitamin D is 0.07 after adjusted for age at blood draw, season of blood draw, lab batch, cohort.
doi:10.1371/journal.pone.0035211.t005
Table 6. Odds ratios of BCC by quartile of plasma vitamin D concentrations in NHS and NHS II (stratified by pigmentation).
pigmentation 25-Hydroxyvitamin D concentrations, ng/mL
c
P for trend
1st quartile 2nd quartile 3rd quartile 4th quartile
Light pigmentation
n, case/control 46/522 53/531 81/488 97/498
OR
a 1.00(reference) 1.08(0.69–1.69) 1.84(1.20–2.81) 2.35(1.53–3.61) ,.0001
OR
b 1.00(reference) 1.08(0.69–1.68) 1.81(1.18–2.78) 2.31(1.50–3.56) ,.0001
Dark pigmentation
n, case/control 57/488 72/491 85/520 94/518
OR
a 1.00(reference) 1.26(0.84–1.91) 1.38(0.92–2.08) 1.84(1.20–2.82) 0.005
OR
b 1.00(reference) 1.26(0.83–1.91) 1.38(0.91–2.08) 1.85(1.21–2.85) 0.005
aAdjusted for age at blood draw, season of blood draw, lab batch, cohort.
bAdjusted for age at blood draw, season of blood draw, lab batch, cohort, UVB flux.
cP for interaction between UVB flux and 25-hydroxyvitamin D is 0.15 after adjusted for age at blood draw, season of blood draw, lab batch, cohort.
doi:10.1371/journal.pone.0035211.t006
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plasma 25(OH)D measured over 3 years and over 10–11 years
were 0.72 and 0.50, respectively [31]. This indicates that a single
25(OH)D measurement is fairly reproducible over years and
reasonably reflects long-term vitamin D status. It is well known
that sun exposure is the main cause of skin cancers. Therefore,
plasma 25(OH)D levels may predict the risk of non-melanoma skin
cancer.
Recently, Eide et al.[10] reported a positive relationship
between plasma levels of 25(OH)D and non-melanoma skin
cancer (adjusted OR, 1.8; 95% CI, 1.1–2.9), including SCC and
BCC, in a study of 3223 white health maintenance organization
patients who sought advice about the risk of osteoporosis or low
bone density. The 25(OH)D levels were similarly positively
associated with non-melanoma skin cancer risk at anatomical
locations less exposed to UV (adjusted OR, 2.2; 95% CI, 0.7–7.0).
In another nested case-control study, Asgari et al. [11] also found
an increased risk of BCC with higher vitamin D levels among 220
BCC patients and 220 matched controls from the Kaiser
Permanente Northern California Health Maintenance Organiza-
tion (adjusted OR, 2.09; 95% CI, 0.95–4,58). The results of this
study support the findings from Eide et al. and Asgari et al., with
similar risk estimated for BCC. However, Tang et al. [9] found an
inverse association between higher plasma 25(OH)D levels and
risk of non-melanoma skin cancer (OR, 0.6; 95% CI, 0.37–0.98)
among 930 white men from the Osteoporotic Fractures in Men
Study. It should be noted that all the participants in this study and
most of the patients of Eide et al. were women, but the participants
in study of Tang et al. were men. Furthermore, the cohorts in our
study were followed up for more than 10 years, and the Eide et al.
cohort was followed for almost 10 years, but the patients of Tang
et al. were followed up for only 5 years. Lastly, our study had the
largest sample size. These differences may explain the variations
between the results in this study and those of Tang et al.
Stratified analysis on season suggests that 25(OH)D is positively
associated with BCC risk among women whose blood was
collected outside the summer months. In addition, we observed
that the associations between plasma 25(OH)D and BCC risk were
stronger among women from areas with less UVB flux. Similar to
previous report [32], our data support that plasma 25(OH)D could
reasonably reflect long-term vitamin D status more accurately
outside the summer season or in areas of less UVB flux. In a case-
control study, an inverse association between 25(OH)D and lung
cancer was also found only among those whose blood was drawn
during the darker months [33].
Vitamin D may be of importance in skin cancer development.
Although the data from various types of cancer suggest a benefit
from high vitamin D levels, they could be a marker of high sun
exposure and an increased risk of skin cancer. There is in vitro
evidence that vitamin D treatment decreases cell growth and
metastasis [15,16], but most of the cases studied were melanoma.
Evidence in vitro for the role of vitamin D in non-melanoma skin
cancer is still limited. Mice with inactivated vitamin D receptor
had more non-melanoma skin cancer [34]. Vitamin D3 inhibited
the proliferation of basal cell carcinomas by inhibiting the
hedgehog signaling pathway [16]. The evidence in humans of
a positive relationship between vitamin D and non-melanoma skin
cancer suggests that UV exposure may have a predominant
adverse influence that exceeds any putative benefit from the higher
levels of vitamin D.
The strengths of the current study include its prospective design,
large well-characterized study population, long follow-up duration,
and data on potential confounders. The limitation is that blood
samples were not assayed at the same time and in the same
laboratory, although we have controlled for batch variation in the
multivariate models.
In conclusion, this prospective study found a positive association
between plasma 25(OH)D levels and risk of non-melanoma skin
cancer. Additionally, for BCC, this association was more apparent
among women with blood collection outside the summer season,
women from areas with less UVB flux, and light-pigmented
women. Considering that most circulating vitamin D is due to sun
exposure, the positive association between plasma vitamin D and
non-melanoma skin cancer is confounded by sun exposure. Our
results suggest that one-time measurement of plasma vitamin D
may reasonably reflect long-term sun exposure and predict the risk
of non-melanoma skin cancer.
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